Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19Original Article Published on 2020-01-012022-10-31 Journal: Gastroenterology and Hepatology From Bed to Bench [Category] COVID-19, [키워드] 6LU7 Algorithm anti-CoV drug antiprotease applied approach approved binding binding site calculated Cobicistat compounds conducted conformation conformations COVID-19 demonstrated determine docking docking scores docking study DOS drug drugs Effectiveness exhibited FDA FDA approved drug In-vitro inhibitor Interaction Ligand main protease molecular docking molecular target MPro Mpro/6LU7 potential therapeutic agents protease Protease inhibitor Protein Repository Result RMSD screened selected selected drug Simeprevir Spread Temoporfin the disease Treatment Viral antiprotease drugs was obtained was performed with COVID-19 PMC 바로가기 [Article Type] Original Article
Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy프로테아제 억제제 단독 요법의 PIVOT 시험에서 HIV-1 프로테아제의 차세대 시퀀싱Article Published on 2018-04-012022-09-06 Journal: Journal of Clinical Virology [Category] Communicable Disease, [키워드] Algorithm Antiretroviral therapy clinically Combination combination therapy Coverage described drug drug susceptibility Evidence examined frequencies Frequency frozen plasma Highlights HIV HIV-1 Laboratory leads Local low frequency median time Median viral load methodology monotherapy Mutation mutations next generation sequencing NGS objective Patient patients performed phenotypic plasma sample predict predicted Primary outcome protease Protease inhibitor Public Health England randomisation randomised reported resistance Result Ritonavir Sanger sequencing selected Sequencing Stanford Study design study drug suppressed susceptibility tested the median threshold Trial variant Viral Viral load was performed [DOI] 10.1016/j.jcv.2018.02.003 PMC 바로가기 [Article Type] Article
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialHIV의 2차 치료를 위한 로피나비르 + 뉴클레오시드 역전사효소 억제제, 로피나비르 + 랄테그라비르 또는 로피나비르 단독요법(EARNEST): 무작위 대조 시험의 144주 추적 결과Article Published on 2018-01-012022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] adverse event African AID analysed Analysis Antiretroviral therapy ART assigned best clinical Combination combination therapy completion computer-generated cooperation country criteria Developing development Efficacy eligibility European event finding FIVE Follow-up funding GRADE grade 3 group HIV-infected people inferiority inhibitor inhibitors intervention group ISRCTN Kenya less limit Lopinavir Medical Research Council Modification monotherapy no difference non-inferiority non-inferiority margin nucleoside offer offered outcome participant partnership Patient per day primary analysis Primary outcome protease Protease inhibitor raltegravir randomisation randomised controlled trial Randomly receive recent regimen regimens Registered Ritonavir screened sequence Serious Adverse Events Swedish Treatment treatment of HIV Trial two-sided α Uganda Viral Viral load viral loads Virological WHO WHO criteria WHO guideline Zimbabwe [DOI] 10.1016/S1473-3099(17)30630-8 PMC 바로가기 [Article Type] Article
Identification of Proteases and Protease Inhibitors in Allergenic and Non-Allergenic PollenArticle Published on 2017-06-052023-08-30 Journal: International Journal of Molecular Sciences [Category] E형 간염, [키워드] allergenicity pollen transcriptome protease Protease inhibitor [DOI] 10.3390/ijms18061199 PMC 바로가기 [Article Type] Article
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial공중 보건 접근법에서 뉴클레오시드 역전사효소 억제제 교차 내성 및 2차 항레트로바이러스 요법의 결과: 무작위, 공개, EARNEST 시험 내 관찰 분석Articles Published on 2017-05-082022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] AID Analysis Antiretroviral therapy ART assigned association baseline calculated clinical cooperation Cross-resistance Developing development European Evidence expected finding Follow-up funding Genotype genotypic greater impair inhibitor ISRCTN Lopinavir Medical Research Council monotherapy nucleoside Open-label outcome over partnership Patient patients with HIV predict predicted protease Protease inhibitor public health raltegravir randomised Randomised trial Randomly Registered Ritonavir sub-Saharan Africa Support Swedish tested therapy Treatment outcome Trial Viral Viral load Virological virological outcome virological outcomes WHO WHO criteria with HIV [DOI] 10.1016/S2352-3018(17)30065-6 PMC 바로가기 [Article Type] Articles
Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitorsOriginal Article Published on 2017-01-222022-10-30 Journal: Journal of Enzyme Inhibition and Medicinal Chemist [Category] Coronavirus, [키워드] Broussonetia papyrifera 3CL pro Analysis binding constant Broussonetia candidate Compound coronavirus cysteine proteases feature inhibitor inhibitory activity Interaction investigated kinetic Papain-like protease polyphenol protease Protease inhibitor responsible SARS [DOI] 10.1080/14756366.2016.1265519 PMC 바로가기 [Article Type] Original Article
Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease InhibitorResearch Article Published on 2016-03-302022-10-29 Journal: PLoS Pathogens [Category] Coronavirus, [키워드] 3CLpro Animal coronaviruses Antiviral compound antiviral drug antiviral drugs Antiviral treatment cause caused cell tropism contributed coronavirus coronavirus Coronavirus infection Coronavirus infections Cross-species transmission death disease Diseases effective Efficacy and safety evaluated experimental evidence facilitate fatal disease fatality feature Feline infectious peritonitis Fever full recovery Health Host Human humans immune response Immune-mediated infect inflammatory disease inhibitor Laboratory less lymphopenia mammalian measure Mild Mutation other coronavirus pathogen Pathogenesis progression protease Protease inhibitor recombination rate reduction in Replication reported required respiratory resulting returned reversal risk Significant T cells therapeutic therapeutic efficacy therapeutic strategy tissue Treatment viable treatment viral titer virulence virulent virus virus replication [DOI] 10.1371/journal.ppat.1005531 PMC 바로가기 [Article Type] Research Article
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialHIV 감염의 장기 관리를 위한 프로테아제 억제제 단독 요법: 무작위, 대조, 공개, 비열등성 시험Articles Published on 2015-09-142022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] 1:1 adverse event age Antiretroviral therapy ART baseline benefit block CD4 Cell Clinical management Clinical outcome clinical risk Combination combination treatment computer-generated Controlled darunavir defined drug drug resistance enrolled finding Frequency funding Genetic GRADE grade 3 HIV HIV infection inferiority inhibitor Intention intention to treat international standard Kaplan-Meier Kaplan-Meier analysis Lopinavir maintain management monotherapy non-inferiority non-inferiority margin non-inferiority trial number once daily Open-label parallel-group participant positive Pragmatic preserved Primary outcome Probability Protease inhibitor protease inhibitors public sector randomisation randomisation list randomised Randomly rebound Registered Ritonavir Serious Adverse Events shown Standard stratified suppressed the patient therapy toxic effects Treatment treatment failure Trial Viral Viral load virus [DOI] 10.1016/S2352-3018(15)00176-9 PMC 바로가기 [Article Type] Articles
Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent MannerResearch Article Published on 2014-11-062022-10-29 Journal: PLoS Pathogens [Category] Coronavirus, [키워드] Cell cell entry Clathrin-mediated endocytosis cleavage conformational change coronavirus coronavirus CoV CoVs demonstrated endocytosed endosomal maturation endosomal pH entry pathway expressing furin furin cleavage site fusion fusion peptide fusion protein gene silencing Genome Host host cell host cell membrane induce Infection influenza A virus inhibited introduced investigated late endosomes less lysosomal protease lysosomal proteases lysosome membrane fusion MERS MERS-CoV MHV microenvironment mouse hepatitis murine hepatitis virus negatively affected occur pathogen plasma membrane predicted previous study promote protease Protease inhibitor Protein proteolytic cleavage Proteolytic processing reporter required S protein shown siRNA Specific the S protein upstream vesicular stomatitis virus virus virus while zoonotic [DOI] 10.1371/journal.ppat.1004502 PMC 바로가기 [Article Type] Research Article
SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral RegimenSWIFT: 항레트로바이러스 요법을 포함하는 강화된 프로테아제 억제제를 사용하는 바이러스학적으로 억제된 HIV-1 감염 환자에서 라미부딘/아바카비르에서 엠트리시타빈/테노포비어로 전환하는 것의 효능 및 안전성을 평가하기 위한 전향적 48주 연구HIV/AIDS Published on 2013-06-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] 3TC/ABC 95% confidence interval abacavir addition Arm ARMS backbone baseline characteristics calculated CD4 Characteristics cholesterol compared Containing Decline decrease Decreased defined Efficacy and safety EGFR emtricitabine emtricitabine/tenofovir epidermal epidermal growth factor evaluate FTC/TDF fumarate GFR greater growth factor HIV patient HIV patients HIV-1 Human immunodeficiency virus immunodeficiency virus improvement Improvements Infected inhibitor lamivudine LDL Lipid lipids Lipoproteins Low-density lipoprotein low-density lipoproteins male median median age nucleoside Open-label parameter Patient PI primary endpoint Prospective Protease inhibitor Randomized rebound receiving receptor regimen reverse transcriptase risk score Ritonavir RNA RTV Safety study drug subject suppressed switch switching tenofovir disoproxil fumarate TG The United States threshold Total cholesterol transcriptase treated treatment difference Triglyceride triglycerides United States virologic failure Virologic suppression [DOI] 10.1093/cid/cis1203 PMC 바로가기 [Article Type] HIV/AIDS